323 related articles for article (PubMed ID: 26079417)
1. The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment.
Tosto G; Zimmerman ME; Hamilton JL; Carmichael OT; Brickman AM;
Alzheimers Dement; 2015 Dec; 11(12):1510-1519. PubMed ID: 26079417
[TBL] [Abstract][Full Text] [Related]
2. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment.
Guzman VA; Carmichael OT; Schwarz C; Tosto G; Zimmerman ME; Brickman AM;
Alzheimers Dement; 2013 Oct; 9(5 Suppl):S124-31. PubMed ID: 23375566
[TBL] [Abstract][Full Text] [Related]
3. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
[TBL] [Abstract][Full Text] [Related]
4. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
[TBL] [Abstract][Full Text] [Related]
5. CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease.
Walsh P; Sudre CH; Fiford CM; Ryan NS; Lashley T; Frost C; Barnes J;
Neurobiol Aging; 2020 Jul; 91():5-14. PubMed ID: 32305782
[TBL] [Abstract][Full Text] [Related]
6. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
van Waalwijk van Doorn LJC; Ghafoorian M; van Leijsen EMC; Claassen JAHR; Arighi A; Bozzali M; Cannas J; Cavedo E; Eusebi P; Farotti L; Fenoglio C; Fortea J; Frisoni GB; Galimberti D; Greco V; Herukka SK; Liu Y; Lleó A; de Mendonça A; Nobili FM; Parnetti L; Picco A; Pikkarainen M; Salvadori N; Scarpini E; Soininen H; Tarducci R; Urbani A; Vilaplana E; Meulenbroek O; Platel B; Verbeek MM; Kuiperij HB
J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
[TBL] [Abstract][Full Text] [Related]
7. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Eloyan A; Thangarajah M; An N; Borowski BJ; Reddy AL; Aisen P; Dage JL; Foroud T; Ghetti B; Griffin P; Hammers D; Iaccarino L; Jack CR; Kirby K; Kramer J; Koeppe R; Kukull WA; La Joie R; Mundada NS; Murray ME; Nudelman K; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Rogalski E; Salloway S; Sha S; Turner RS; Wingo TS; Wolk DA; Womack K; Beckett L; Gao S; Carrillo MC; Rabinovici G; Apostolova LG; Dickerson B; Vemuri P;
Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S89-S97. PubMed ID: 37491599
[TBL] [Abstract][Full Text] [Related]
8. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?
Provenzano FA; Muraskin J; Tosto G; Narkhede A; Wasserman BT; Griffith EY; Guzman VA; Meier IB; Zimmerman ME; Brickman AM;
JAMA Neurol; 2013 Apr; 70(4):455-61. PubMed ID: 23420027
[TBL] [Abstract][Full Text] [Related]
9. Association of Regional White Matter Hyperintensities With Longitudinal Alzheimer-Like Pattern of Neurodegeneration in Older Adults.
Rizvi B; Lao PJ; Chesebro AG; Dworkin JD; Amarante E; Beato JM; Gutierrez J; Zahodne LB; Schupf N; Manly JJ; Mayeux R; Brickman AM
JAMA Netw Open; 2021 Oct; 4(10):e2125166. PubMed ID: 34609497
[TBL] [Abstract][Full Text] [Related]
10. The association between white matter hyperintensities and amyloid and tau deposition.
Alban SL; Lynch KM; Ringman JM; Toga AW; Chui HC; Sepehrband F; Choupan J;
Neuroimage Clin; 2023; 38():103383. PubMed ID: 36965457
[TBL] [Abstract][Full Text] [Related]
11. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions.
Weaver NA; Doeven T; Barkhof F; Biesbroek JM; Groeneveld ON; Kuijf HJ; Prins ND; Scheltens P; Teunissen CE; van der Flier WM; Biessels GJ;
Neurobiol Aging; 2019 Dec; 84():225-234. PubMed ID: 31500909
[TBL] [Abstract][Full Text] [Related]
12. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
[TBL] [Abstract][Full Text] [Related]
13. Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence.
Brickman AM; Zahodne LB; Guzman VA; Narkhede A; Meier IB; Griffith EY; Provenzano FA; Schupf N; Manly JJ; Stern Y; Luchsinger JA; Mayeux R
Neurobiol Aging; 2015 Jan; 36(1):27-32. PubMed ID: 25155654
[TBL] [Abstract][Full Text] [Related]
14. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
[TBL] [Abstract][Full Text] [Related]
15. White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network.
Lee S; Viqar F; Zimmerman ME; Narkhede A; Tosto G; Benzinger TL; Marcus DS; Fagan AM; Goate A; Fox NC; Cairns NJ; Holtzman DM; Buckles V; Ghetti B; McDade E; Martins RN; Saykin AJ; Masters CL; Ringman JM; Ryan NS; Förster S; Laske C; Schofield PR; Sperling RA; Salloway S; Correia S; Jack C; Weiner M; Bateman RJ; Morris JC; Mayeux R; Brickman AM;
Ann Neurol; 2016 Jun; 79(6):929-39. PubMed ID: 27016429
[TBL] [Abstract][Full Text] [Related]
16. White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia.
Dadar M; Manera AL; Ducharme S; Collins DL
Neurobiol Aging; 2022 Mar; 111():54-63. PubMed ID: 34968832
[TBL] [Abstract][Full Text] [Related]
17. Entorhinal Perfusion Predicts Future Memory Decline, Neurodegeneration, and White Matter Hyperintensity Progression in Older Adults.
Bangen KJ; Thomas KR; Sanchez DL; Edmonds EC; Weigand AJ; Delano-Wood L; Bondi MW;
J Alzheimers Dis; 2021; 81(4):1711-1725. PubMed ID: 33967041
[TBL] [Abstract][Full Text] [Related]
18. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.
Bos I; Verhey FR; Ramakers IHGB; Jacobs HIL; Soininen H; Freund-Levi Y; Hampel H; Tsolaki M; Wallin ÅK; van Buchem MA; Oleksik A; Verbeek MM; Olde Rikkert M; van der Flier WM; Scheltens P; Aalten P; Visser PJ; Vos SJB
Alzheimers Res Ther; 2017 Dec; 9(1):101. PubMed ID: 29284531
[TBL] [Abstract][Full Text] [Related]
19. Regional White Matter Hyperintensity Influences Grey Matter Atrophy in Mild Cognitive Impairment.
Vipin A; Foo HJL; Lim JKW; Chander RJ; Yong TT; Ng ASL; Hameed S; Ting SKS; Zhou J; Kandiah N
J Alzheimers Dis; 2018; 66(2):533-549. PubMed ID: 30320575
[TBL] [Abstract][Full Text] [Related]
20. The Brain Chart of Aging: Machine-learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans.
Habes M; Pomponio R; Shou H; Doshi J; Mamourian E; Erus G; Nasrallah I; Launer LJ; Rashid T; Bilgel M; Fan Y; Toledo JB; Yaffe K; Sotiras A; Srinivasan D; Espeland M; Masters C; Maruff P; Fripp J; Völzk H; Johnson SC; Morris JC; Albert MS; Miller MI; Bryan RN; Grabe HJ; Resnick SM; Wolk DA; Davatzikos C;
Alzheimers Dement; 2021 Jan; 17(1):89-102. PubMed ID: 32920988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
